{"entity":{"id":"paper-morpho-gilteritinib-levis-jco-2024","kind":"paper","name":"MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia","aka":[],"tldr":"Two years of the FLT3 blocker gilteritinib after a stem-cell transplant did not significantly reduce relapses across all patients, but it clearly did in the half whose highly sensitive blood tests still found traces of the leukaemia, one of the first results to support choosing post-transplant treatment by residual disease.","summary":"Randomised, double-blind, placebo-controlled phase 3 trial (BMT CTN 1506) in 356 adults with FLT3-ITD acute myeloid leukaemia in first remission after allogeneic transplant, assigned to gilteritinib 120 mg daily or placebo for 24 months. The primary endpoint was relapse-free survival; measurable residual disease for FLT3-ITD was assessed before and after transplant.\n\nRelapse-free survival favoured gilteritinib but was not statistically significant (hazard ratio 0.679, p 0.0518). In the prespecified 50.5 percent of participants with detectable residual disease the hazard ratio was 0.515 (p 0.0065); those without detectable disease showed no benefit (hazard ratio 1.213).","asOf":"2026-09-22","links":[{"label":"J Clin Oncol 2024","url":"https://doi.org/10.1200/JCO.23.02474"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38471061/"}],"tags":[],"related":[],"cancers":["aml-flt3","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["gilteritinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["morpho"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/JCO.23.02474","pmid":"38471061","authors":"Levis MJ, Hamadani M, Logan B, et al.","paperType":"rct","findings":["Relapse-free survival hazard ratio 0.679 (95% CI 0.459 to 1.005; two-sided p 0.0518) for gilteritinib versus placebo.","MRD detectable before or after transplant (50.5 percent of participants): hazard ratio 0.515 (95% CI 0.316 to 0.838; p 0.0065).","MRD not detectable: hazard ratio 1.213 (95% CI 0.616 to 2.387; p 0.575)."],"whatItMeans":"Post-transplant FLT3 inhibitor maintenance helps patients with detectable FLT3-ITD residual disease and can probably be spared in those without it; guidelines now describe maintenance for MRD-positive disease on this evidence.","caveats":["The primary endpoint was not met; the MRD finding is a prespecified subgroup analysis.","Conditioning intensity and regional practice differences affected the size of the benefit in later analyses."],"changedPractice":true,"participants":356},"route":"/key-papers/paper-morpho-gilteritinib-levis-jco-2024/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"}],"drug":[{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/"}],"trial":[{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}